At the conclusion of the session, the learner will have an increased understanding of

• the biologic, genetic, and preclinical rationale for a FXI/Xia-targeted anticoagulation strategy
• the proposed mechanistic separation of impacts on hemostasis and thrombosis by inhibitors of Factor XI/Xia
• the limitations of currently approved anticoagulants in the provision of stroke prevention in atrial fibrillation (SPAF)
• current and emerging data on FXI/XIa-targeted anticoagulants in SPAF